Elekta (STO:EKTA B) said today it won Health Canada approval for its Leksell Gamma Knife Icon radiosurgery system.
The Stockholm, Sweden-based company touted its Leksell Gamma Knife Icon radiosurgery system as the only SRS system designed specifically for targeting brain tissue. The Icon is the 6th generation version of the radiosurgery system from the Elekta.
“Robust clinical evidence from more than one million procedures supports Gamma Knife as the most precise SRS platform in the world. Icon was designed with multiple technology upgrades that enable improved work flow and efficiencies. As part of our ongoing commitment to improving outcomes for patients and clinicians with treatable neurological conditions worldwide, we are pleased that Icon will now be available in Canada,” North America regional exec VP Bill Yaeger said in a press release.
The Leksell Gama Knife Icon features the company’s Adaptive DoseControl, as well as high-definition motion management technologies to improve treatment accuracy and efficiency, Elekta said.
“We are pleased to soon offer our patients the latest advance in SRS technology. The image guidance and frameless features of Gamma Knife Icon allow us to treat patients who were not candidates for SRS therapy with older technologies. Through our experience participating in the pre-approval validation of this system, we had the opportunity to experience how real-time CT imaging enables sub-millimeter accuracy in targeting tumors. This degree of precision is especially critical when targeting lesions in the brain, where sparing healthy tissue is essential for reducing side effects and protecting normal brain function,” Dr. Arjun Sahgal of Toronto’s Sunnybrook Health Sciences Centre said in a prepared statement.
Earlier this month, Elekta said it won FDA 510(k) clearance for its Venezia applicator for gynecological brachytherapy, now cleared for the treatment of advanced-stage cervical cancer.
The company’s Venezia device is designed to facilitate pre-defined, consistent needle placement for interstitial brachytherapy and to allow operating clinicians the ability to access tumors that extend outside of the cervix.
